AVROBIO, Inc. Overview
Pro stress-test →AVROBIO develops gene therapies by introducing functional copies of affected genes into patients' own hematopoietic stem cells (HSCs), with the goal of durably expressing therapeutic proteins throughout the body, including the central nervous system. The company's pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease.
Strategic Profile
Pro stress-test →AVROBIO's proprietary plato® gene therapy platform is scalable for planned global commercialization. The company was acquired by Tectonic Therapeutic on June 20, 2024, positioning it within a combined entity focused on next-generation therapeutic approaches for rare genetic diseases.
Competitive Landscape
Pro stress-test →Competitors in the rare genetic disease and gene therapy space include Orchard Therapeutics, Ultragenyx Pharmaceutical, NexImmune, and Arno Therapeutics. Direct competitors for lysosomal storage disorder therapies include companies developing AAV and lentiviral gene therapy platforms.
Industry Context
AVROBIO, Inc. operates in Gene Therapy / Rare Disease Therapeutics.
Key facts
Founded: 2015 · Headquarters: Cambridge, MA · Employees: 22 · Revenue: $25.8M